Clinical correlation between hypercoagulability and thrombo-embolic phenomena.
A study of the coagulolytic balance as well as platelet aggregation was carried out in 64 nephrotic patients. The data were correlated, in a prospective attempt, with the clinical demonstration of thrombo-embolic events. Activating factors (factors I, VIIIc, VIIIr:Ag) were increased as well as certain clotting inhibitors, alpha-1-antitrypsin and alpha-2-macroglobulin. There was a platelet hyperaggregability in 31.5% of our patients. Thrombo-embolic complications occurred in six subjects (9%). The data of these six patients were compared with that of the other patients; no significant correlation were found between clotting abnormalities and thrombosis. Low level of ATm (less than 0.8 U.Fr) and severe hypoalbuminemia (less than 20 g/liter) were of no predictive value for the occurrence of thrombo-embolic events.
D000328:Adult; D000368:Aged; D000941:Antigens / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation; D005169:Factor VIII / Q000276:immunology / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood / Q000150:complications*; D010974:Platelet Aggregation; D011446:Prospective Studies; D012709:Serum Albumin / Q000378:metabolism; D013923:Thromboembolism / Q000209:etiology*; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000378:metabolism; D014841:von Willebrand Factor
D000941:Antigens; D012709:Serum Albumin; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D014841:von Willebrand Factor; D000990:Antithrombin III; D005169:Factor VIII; D005340:Fibrinogen